"Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response" by J E Stein

Selected Works of Walter J. Urba, MD, PhD

Article

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response

Annals of Oncology (2019)

J E Stein, Johns Hopkins University
A Soni, Johns Hopkins University
L Danilova, Johns Hopkins University
T R Cottrell, Johns Hopkins University
T F Gajewski, University of Chicago
F S Hodi, Harvard University
S Bhatia, Fred Hutchinson Cancer Research Center
W J Urba, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, USA
W H Sharfman, Johns Hopkins University
M Wind-Rotolo, Bristol-Myers Squibb
R Edwards, Bristol-Myers Squibb
E J Lipson, Johns Hopkins University
J M Taube, Department of Dermatology, Johns Hopkins University SOM, Baltimore, USA

Link

Disciplines

Publication Date

January 23, 2019

DOI

10.1093/annonc/mdz019

Citation Information

J E Stein, A Soni, L Danilova, T R Cottrell, et al.. "Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response" Annals of Oncology (2019)
Available at: http://works.bepress.com/walter-urba/255/